No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - General
Roche Holding AG is a global healthcare company specializing in pharmaceuticals and diagnostics, with significant operations in Switzerland, Germany, the United States, Austria, the Netherlands, the United Kingdom, France, Belgium, and various other international regions. Its comprehensive portfolio of pharmaceutical products addresses conditions across oncology, neuroscience, infectious diseases, immunology, cardiovascular and metabolism, ophthalmology, and respiratory health. Additionally, the company develops treatments for specific ailments such as anemia, dermatological conditions, hemophilia, inflammatory and autoimmune disorders, neurological conditions, and transplantation. The diagnostics division offers a range of in-vitro tests essential for identifying numerous diseases, including cancer, diabetes, COVID-19, hepatitis, and human papillomavirus (HPV). Beyond tests, it also supplies crucial diagnostic instruments and reagents. Founded in Basel, Switzerland, in 1896, the company maintains its headquarters there.
www.roche.comNo one on the platform currently holds ROG.SW.
No tracked institution reports a position in ROG.SW as of their last filing.
No one on the platform has traded ROG.SW yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 25.2% | 25.2% | 29.6% | — | — | — |
| Rev. Growth % | -1.4% | 1.1% | ||||
| Profit Margin % | 20.9% | 18.9% | 19.1% | |||
| Free Cash Flow Margin % | 22.9% | 22.4% | 23.5% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $62.8B | +1.4% | $20.13 | $18.46–$21.54 | — | 14 |
| 2027 | $65.4B | +4.2% | $21.68 | $20.02–$23.00 | — | 14 |
| 2028 | $68.8B | +5.2% | $23.75 | $21.36–$25.06 | — | 9 |
| 2029 | $73.1B | +6.3% | $26.22 | $24.81–$27.69 | — | 3 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 3 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-01-29 | $8.58 | $8.38 | -2.3% |
| 2025-07-24 | $10.46 | $11.08 | +5.9% |
| 2025-01-30 | $8.40 | $8.57 | +2.0% |
| 2024-10-23 | $9.37 | $7.78 | -17.0% |
| 2024-07-25 | $9.37 | $10.23 | +9.2% |
| 2023-11-29 | $10.40 | $8.88 | -14.6% |
| 2023-10-19 | $10.40 | $10.10 | -2.9% |
| 2022-06-30 | $11.02 |
| $10.53 |
| -4.4% |
| +0.00% |
| $1.0B |
| — |
| GALE.SWGalenica AG | $83.40 | +0.54% | $4.2B | — |
| NOVN.SWNovartis AG | $113.92 | +1.68% | $216.5B | — |
Source: Financial Modeling Prep · peers by sector/industry